- In 2019, PerkinElmer, Inc. received approval from the US FDA EUROIMMUN Anti-Tissue Transglutaminase ELISA to help clinicians confirm or exclude a celiac disease diagnosis.
This report aims to provide detailed insights into the global autoimmune disease diagnosis market. It provides valuable information on the type, procedure, application, and region in the market. Furthermore, the information for these segments, by region, is also presented in this report. Leading players in the market are profiled to study their product offerings and understand the strategies undertaken by them to be competitive in this market.
Revenue Growth Analysis:
The global autoimmune disease diagnosis industry size is projected to reach USD 6.3 billion by 2025 from USD 4.1 billion in 2020, growing at a CAGR of 8.9% from 2020 to 2025
Download PDF Brochure:
Key Factors Driving Market Growth:
The high incidence of autoimmune diseases, increasing awareness about autoimmune diseases, and the growth in research on autoimmune diseases, are driving the growth of the global market. Moreover, the use of biosensors for autoimmune disease diagnosis is expected to offer significant growth opportunities to the autoimmune disease diagnosis market players in the coming years.
The competitive landscape includes the analysis of the key growth strategies adopted by major players to expand their global presence and increase their shares in the market. The key growth strategies adopted by the top players in the market include product launches and approvals, agreements, expansions, and acquisitions. Product approvals and launches were the most widely adopted growth strategies by market players in the last three years to garner a larger share of the market.
- Thermo Fisher Scientific (US),
- Siemens (Germany),
- Abbott (US),
- Danaher (US),
- Bio-Rad Laboratories (US),
- Grifols (Spain),
- Trinity Biotech (Ireland),
- Werfen (Spain),
- HYCOR Biomedical (US),
- EUROIMMUN AG (Germany),
- Oncimmune (UK),
- HTG Molecular Diagnostics (US)
Get Crucial Industry Insights:
Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.